Wei Weifeng, Zhang Mi, Lin Yiyuan, Li Ziyin, Luo Wenbo, Zhao Weihua, Zhuang Jing, Zhao Weining, Xu Zhixue, Li Gaomin, Zeng Wenjing, Huang Liping, Tan Yan, Yu Zhiying, Li Guanglei
Shenzhen Dapeng New District Maternity and Child Health Hospital, Shenzhen, China.
Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
Front Microbiol. 2025 Mar 12;16:1539209. doi: 10.3389/fmicb.2025.1539209. eCollection 2025.
Cervical cancer is the fourth most commonly diagnosed malignancy among women globally, with HPV infection being the primary cause. Large-scale HPV screening is crucial for early detection, as appropriate intervention in HPV-positive individuals can significantly reduce cervical cancer incidence and mortality.
Data were extracted from the Shenzhen Maternal and Child Health Management Information System, covering 18,667 HPV infection and cervical cancer screening instances among 15,850 women from January 1, 2020, to December 31, 2023. HPV prevalence and corresponding 95% confidence intervals (CIs) were calculated using SPSS (version 27.0).
From January 2020 to December 2023, the overall HPV infection rate was 12.39%, with a notably higher rate of 23.38% in women over 60 years. The hr-HPV infection rate was 12.99%, with HPV types 52, 58, 16, 51, and 68 being the most common. Among women with positive ThinPrep Cytologic Test (TCT) results, the hr-HPV infection rate was 53.37%. In women with positive cervical histopathology, the hr-HPV infection rate reached 95.95%. With increased HPV vaccination doses, the infection rates of HPV16, 18, 52, 58, 51, 31, 33, 45, 6, and 11 decreased among individuals under 30, but increased in those over 45.
These findings suggest that enhancing HPV vaccination coverage and cervical cancer screening, especially for women over 45, are effective strategies to reduce hr-HPV infection rates and cervical cancer incidence in this region.
宫颈癌是全球女性中第四大最常被诊断出的恶性肿瘤，人乳头瘤病毒（HPV）感染是主要病因。大规模HPV筛查对于早期发现至关重要，因为对HPV阳性个体进行适当干预可显著降低宫颈癌的发病率和死亡率。
数据取自深圳妇幼健康管理信息系统，涵盖2020年1月1日至2023年12月31日期间15850名女性的18667例HPV感染和宫颈癌筛查情况。使用SPSS（版本27.0）计算HPV感染率及相应的95%置信区间（CI）。
2020年1月至2023年12月，总体HPV感染率为12.39%，60岁以上女性的感染率显著更高，为23.38%。高危型HPV（hr-HPV）感染率为12.99%，其中HPV 52、58、16、51和68型最为常见。在薄层液基细胞学检测（TCT）结果为阳性的女性中，hr-HPV感染率为53.37%。在宫颈组织病理学检查结果为阳性的女性中，hr-HPV感染率达到95.95%。随着HPV疫苗接种剂量的增加，30岁以下个体中HPV 16、18、52、58、51、31、33、45、6和11型的感染率下降，但45岁以上个体中的感染率上升。
这些发现表明，提高HPV疫苗接种覆盖率和宫颈癌筛查率，特别是针对45岁以上女性，是降低该地区hr-HPV感染率和宫颈癌发病率的有效策略。
